Ciloa is pleased and proud to announce the launch of its subsidiary, in-EV. The extracellular vesicle research community has expressed interest in Ciloa’s in vivo EV bioengineering technology. Thus in-EV is now making this unique, cutting-edge technology available, providing innovative, high-quality, high-performance tools and services for extracellular vesicle research. Stay tuned, in-EV products will be presented soon! #extracellularvesicles #exosomes #2ndMOVESymposium
The in-EV team is pleased to announce its participation at 2nd MOVE Symposium ahead of the official launch of its e-shop on December 1st, 2024. We will be exclusively presenting our innovative, cutting-edge tools fully dedicated for research on extracellular vesicles. As subsidiary of Ciloa, a pioneer EV company, in-EV benefits from more than 20 years of experience in the EV field and an access to a unique in vivo EV bioengineering technology. After many collaborations with academic and private partners, we decided to share our unique research tools and breakthrough technology with the EV community. Based on our “Quality and Performance” virtuous circle, we offer a wide range of products and solutions: • Standard EVs and bioengineered EVs with labelled luminal cargoes or membrane proteins • Kits for EV purification and EV characterisation • EV purification and EV characterisation services • Bioengineered EVs from a portfolio of more than 100 membrane proteins • EV bioengineering on demand Come and visit us, we will be delighted to present you our first-in-class products and services at our booth from 8 to 11 October at the Belgrade Madlenijanum Theatre. #extracellularvesicles #exosomes #2ndMOVESymposium